Toxicological Sciences 65, 266-275 (2002)
Copyright © 2002 by the Society of Toxicology
SAFETY EVALUATION |
Rodent Nonclinical Safety Evaluation Studies of SCH 58500, an Adenoviral Vector for the p53 Gene
* Drug Safety, Schering-Plough Research Institute, P.O. Box 32, Lafayette, New Jersey 07848-0032;
Preclinical Development and Therapeutic Antibody Discovery, Millennium Pharmaceuticals, Cambridge, Massachusetts 02139;
Drug Metabolism, Schering-Plough Corporation, Kenilworth, New Jersey; and
Drug Safety and Metabolism, Schering-Plough Research Institute, Lafayette, New Jersey 07848
SCH 58500 is a replication-defective recombinant adenoviral vector containing the cloned human wild-type (normal) tumor suppressor gene p53. SCH 58500 is in trials to evaluate potential clinical utility. A series of toxicology studies in rats and mice were conducted via multiple routes of exposure to support these programs. The nonlethal and asymptomatic dose in rats following a 14-day observation period was equal to 7.5 x 107 plaque-forming units (pfu)/kg (5.6 x 1010 particles/kg) by intravenous or intraperitoneal route and was similar by the ip route, following 4 weeks of dosing. The high dose of 1.5 x 109 pfu/kg (1.1 x 1012 particles/kg) was lethal by the iv route and inflammatory to the peritoneal cavity by the ip route. SCH 58500 was rapidly cleared from the systemic circulation in rats (serum t1/2 of 7 to 9 min) following iv administration. Administration by other routes resulted in no (sc) or delayed (ip) serum levels. Since most rats in the iv rat study died within 24 h postdose, another study to evaluate potential mechanisms of toxicity in rats was designed in which rats were killed at intervals following a single iv dosing. A singe high iv dose of SCH 58500 (1.1 x 1012 pfu/kg) was associated with lethargy, soft feces, a ruffled-hair coat, and death within 1 h postdose. Potential mechanisms of toxicity appeared to include a mild coagulopathy and/or vasculopathy, resulting in consumption of platelets and clotting factors, leakage or loss of intravascular fluid, hemoconcentration, electrolyte and/or fluid shifts, a moderate stress and/or inflammatory response, and a mild, direct or indirect toxic effect on liver and/or kidney tissue. These findings suggest a multifocal cause for acute lethality following iv dosing in rats.
Key Words: p53 gene; adenoviral vector; gene therapy; safety evaluation; coagulopathy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. S. Reddy, K. D. Burroughs, L. M. Hales, S. Ganesh, B. H. Jones, N. Idamakanti, C. Hay, S. S. Li, K. L. Skele, A.-J. Vasko, et al. Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers J Natl Cancer Inst, November 7, 2007; 99(21): 1623 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Morrissey, C. Horvath, E. A. Snyder, J. Patrick, N. Collins, E. Evans, and J. S. MacDonald Porcine Toxicology Studies of SCH 58500, an Adenoviral Vector for the p53 Gene Toxicol. Sci., February 1, 2002; 65(2): 256 - 265. [Abstract] [Full Text] [PDF]
|
|